Locally Delivered Antibiotics for the Treatment of Periodontitis
Primary Purpose
Periodontitis
Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Minocycline Topical
Metronidazole Topical Gel
Sponsored by

About this trial
This is an interventional treatment trial for Periodontitis
Eligibility Criteria
Inclusion Criteria:
- Patients suffering from chronic periodontitis with almost similar probing depth bilaterally (≥
- 6 mm) at the selected sites and exhibiting bleeding on probing Patients with no caries and restorations on the selected teeth
- Patients showing effective individual oral hygiene.
Exclusion Criteria:
Patients presenting with history of intake of local and/or systemic antibiotic therapy for the last 3 months
- Patients with known systemic and debilitating diseases (Muscular Dystrophy)
- Patients presenting with known adverse reactions to any component of the test agent
- Patients on anticoagulant therapy
- Pregnant and lactating females
- Smokers
- Patients in a regular use of mouth wash
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Mincycline hydrochloride 2% oral gel
Metronidazole hylcate 0.75 % oral gel
Arm Description
Minocycline will be delivered locally in the periodontal pocket.
Metronidazole gel will be delivered locally in the periodontal pocket.
Outcomes
Primary Outcome Measures
plaque index
To measure the state of oral hygiene as:
0 = No plaque in the gingival area
= A film of plaque adhering to the free gingival margin and adjacent of the tooth
= Moderate accumulation of soft deposits within the gingival pocket
= Abundance of soft matter within the gingival pocket
The Plaque Index is the four gingival areas of the tooth (buccal, lingual/palatal, mesial, distal) given a score from 0-3 and scores were added and divided by four. The plaque index for the individual was obtained by adding the indices for the teeth and divide by the number of teeth examined.
gingival index
To assess the gingival condition and record qualitative chances in the gingiva as:
0 = Normal gingiva
= Mild inflammation - slight change in color and slight edema but no bleeding on probing.
= Moderate inflammation - redness, edema and glazing, bleeding on probing
= Severe inflammation - marked redness and edema, ulceration with tendency to spontaneous bleeding.
The bleeding will be assessed by gently probing along the wall of the soft tissue of the gingival sulcus. To get the gingival index for the tooth, the four areas of the tooth (buccal, lingual/palatal, mesial, distal) are scored by the sum and divided by four. The gingival index for the individual will be obtained by adding the indices of the teeth and divided by the number of teeth examined.
probing depth
The distance from the gingival margin to base of the sulcus. Will be measured at six sites per tooth (mesio-buccal, buccal, disto-buccal, disto-lingual, lingual and mesio-lingual) at all teeth with UNC-15 probe.
IL6
In healthy subjects it ranges from 0.5-5 pg/ml In eosinophilic subjects it ranges from 3-18pg/ml in plasma
Secondary Outcome Measures
Full Information
NCT ID
NCT04125706
First Posted
October 11, 2019
Last Updated
October 13, 2019
Sponsor
Riyadh Elm University
1. Study Identification
Unique Protocol Identification Number
NCT04125706
Brief Title
Locally Delivered Antibiotics for the Treatment of Periodontitis
Official Title
Locally Delivered Antibiotics for the Treatment of Periodontitis Topical Doxycycline Versus Minocycline Gels as an Adjunct to Mechanical Treatment
Study Type
Interventional
2. Study Status
Record Verification Date
October 2019
Overall Recruitment Status
Unknown status
Study Start Date
November 1, 2019 (Anticipated)
Primary Completion Date
July 1, 2020 (Anticipated)
Study Completion Date
September 1, 2020 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Riyadh Elm University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The sample consists of patients with moderate to severe periodontitis who will be subjected to machanical therapy in combination to local antibiotics. The participants will be divided into two groups, mechanical therapy with metronidazole hyclate, and mechanical therapy with minocycline hydrochloride. Both antibiotics will be delivered locally as gels. Outcome measures include probing pocket depth and several gingival indices. IL6 will be also measured for all participants.
Detailed Description
Forty-four patients in the age group of 25-50 years (males and females) who are suffering from periodontitis with almost similar probing depth bilaterally (≥ 6 mm) at the selected sites and exhibiting bleeding on probing.
A written informed consent will be taken from the patients prior to the study.
Each patient will be recalled 4 weeks after completion of both sides supra-gingival scaling, which formed the baseline visit. Plaque scores will be brought to zero, and the probing pocket depth and gingival index, will be recorded on the proforma specially prepared for the purpose.
The selected treatment sites will be then divided into two groups, and sub-gingival SRP will be performed prior to the delivery of the drugs at the test sites.
Group I: Consist of periodontal pockets on the left side of maxillary or mandibular arch and received sub-gingival Minocycline 2% gel.
Group II: Consist of periodontal pockets on the left side of maxillary or mandibular arch and received Metronidazole 0.75% gel.
The right side will be left as a control in both groups Patients will be recalled after 6 weeks from the baseline visit to record the plaque index, gingival index, bleeding index and probing depth (UNC probe 12 mm).
Statistical Analysis:
The unit of measurement in this study is the site, rather than the subject. Student-t test was To compare between Group 1 (Minocycline 2 %) and Group 2 (Metronidazole 0.75 %), Data will check for normality, if the data normally distributed Independent t-test will use to test if there any significant differences between groups, otherwise if not normally Mann -Whitney U-test (Non-parametric) will use to detects the difference.
To achieve 80% power of statistical test to detect the differences between Metronidazole and Minocycline With 5 % level of significant, 19.6 reduction in probing depth (previous study-vi) and standard deviation of 0.23, using the following formula.
n=(2σ^2 〖(Z_(β+Z_(1-α/2) ))〗^2)/d^2 22 per group (minimum sample size) where: σ =0.23 Zβ =0.84 Z(1-α/2) =1.96, d= 19.6%
For objective 2, the statistical test in case of normal data distribution will be paired t test or will use Willcoxon Sign Ranked test if it not normally distributed.
To achieve 80% power of statistical test to detect the differences between Metronidazole and Minocycline. With 5% level of significant.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Periodontitis
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Two parallel groups will receive two different locally delivered antibiotics
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Allocation
Randomized
Enrollment
44 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Mincycline hydrochloride 2% oral gel
Arm Type
Experimental
Arm Description
Minocycline will be delivered locally in the periodontal pocket.
Arm Title
Metronidazole hylcate 0.75 % oral gel
Arm Type
Experimental
Arm Description
Metronidazole gel will be delivered locally in the periodontal pocket.
Intervention Type
Drug
Intervention Name(s)
Minocycline Topical
Other Intervention Name(s)
Dentomycin oral gel will be delivered locally in the periodontal pocket
Intervention Description
Minocycline will be delivered locally in the periodontal pocket
Intervention Type
Drug
Intervention Name(s)
Metronidazole Topical Gel
Other Intervention Name(s)
Roza 0.75% will be delivered locally in the periodontal pocket
Intervention Description
Metronidazole will be delivered locally in the periodontal pocket
Primary Outcome Measure Information:
Title
plaque index
Description
To measure the state of oral hygiene as:
0 = No plaque in the gingival area
= A film of plaque adhering to the free gingival margin and adjacent of the tooth
= Moderate accumulation of soft deposits within the gingival pocket
= Abundance of soft matter within the gingival pocket
The Plaque Index is the four gingival areas of the tooth (buccal, lingual/palatal, mesial, distal) given a score from 0-3 and scores were added and divided by four. The plaque index for the individual was obtained by adding the indices for the teeth and divide by the number of teeth examined.
Time Frame
Baseline to six weeks
Title
gingival index
Description
To assess the gingival condition and record qualitative chances in the gingiva as:
0 = Normal gingiva
= Mild inflammation - slight change in color and slight edema but no bleeding on probing.
= Moderate inflammation - redness, edema and glazing, bleeding on probing
= Severe inflammation - marked redness and edema, ulceration with tendency to spontaneous bleeding.
The bleeding will be assessed by gently probing along the wall of the soft tissue of the gingival sulcus. To get the gingival index for the tooth, the four areas of the tooth (buccal, lingual/palatal, mesial, distal) are scored by the sum and divided by four. The gingival index for the individual will be obtained by adding the indices of the teeth and divided by the number of teeth examined.
Time Frame
Baseline to six weeks
Title
probing depth
Description
The distance from the gingival margin to base of the sulcus. Will be measured at six sites per tooth (mesio-buccal, buccal, disto-buccal, disto-lingual, lingual and mesio-lingual) at all teeth with UNC-15 probe.
Time Frame
Baseline to six weeks
Title
IL6
Description
In healthy subjects it ranges from 0.5-5 pg/ml In eosinophilic subjects it ranges from 3-18pg/ml in plasma
Time Frame
Baseline to six weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
25 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Patients suffering from chronic periodontitis with almost similar probing depth bilaterally (≥
6 mm) at the selected sites and exhibiting bleeding on probing Patients with no caries and restorations on the selected teeth
Patients showing effective individual oral hygiene.
Exclusion Criteria:
Patients presenting with history of intake of local and/or systemic antibiotic therapy for the last 3 months
Patients with known systemic and debilitating diseases (Muscular Dystrophy)
Patients presenting with known adverse reactions to any component of the test agent
Patients on anticoagulant therapy
Pregnant and lactating females
Smokers
Patients in a regular use of mouth wash
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Sasha M Suliman, MSc
Phone
966533215808
Email
sashasuliman@riyadh.edu.sa
First Name & Middle Initial & Last Name or Official Title & Degree
Omer AlKadhi
Email
Omar.AlKadhi@riyadh.edu.sa
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sasha M Suliman, MSc
Organizational Affiliation
Ar Riyad, Saudi Arabia, 11681
Official's Role
Principal Investigator
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Locally Delivered Antibiotics for the Treatment of Periodontitis
We'll reach out to this number within 24 hrs